KIFFIK Lab ™
RAPID CANCER TEST
A novel, non-invasive test for early detection of cancer.



Urgent Need for Improved Cancer Detection

FACT:
Colorectal Cancer (CRC) is the 2nd deadliest cancer in the United States.
FACT:
More than 50 Million people are not screened according to recommendations.
FACT:
Early detection is the key to surviving a cancer diagnosis resulting in a 90% survival rate.
The Patented KIFFIK Technology
PAINLESS, NEEDLE FREE TECHNOLOGY + SIMPLE SELF-APPLICATION
Our patented process painlessly creates temporary micro-openings in the skin to capture pure, biomarker-rich Interstitial Fluid (ISF).

Electroporation

Micro-openings are created in the skin through controlled, mild electroporation. This process leaves no damage to the skin.
Extraction

Next, the KIFFIK Lab uses negative pressure to extract the ISF and collects in in the built-in collection vial.
KIFFIK Lab
THE FUTURE OF COLORECTAL CANCER SCREENING
- Novel Non Invasive Approach: Highly specific aptamers detect colorectal cancer biomarkers in interstitial fluid (ISF).
- Early Detection Focus: Higher sensitivity for early-stage cancer and pre-cancerous adenomas, offering life-saving early intervention.
- Simplified Sample Collection: Simple, at-home, and non-invasive ISF sample collection is easily integrated into routine healthcare, improving patient compliance and reducing barriers.
- Cost-Effective: Lower long-term costs compared to stool-based tests, providing a scalable solution for population-wide screening programs.

-
1. APPLY
- 2. TEST
- 3. RESULTS
The KIFFIK Lab is self-applied to the arm.
Device is turned on.
Collection process begins.
Device is turned on.
Collection process begins.
Cartridge contains KIFFIK aptamer sensor technology.
After collection, the ISF sample is placed onto the test cartridge window.
Results appear in minutes.
If Cancer signals are present, follow up with prescribing clinician.
A SERIES OF INNOVATIONS
The KIFFIK cancer pipeline includes eight rapid tests for early cancer biomarker detection.
